July 5, 2017– ApoPharma welcomes submissions to its 14th Annual Iron Warriors Art Contest until the newly extended October 27, 2017 deadline. The goal of this contest is to raise awareness about thalassemia, to encourage the community to chelate, and to give the thalassemia community around the world the opportunity to share their artistic expression and […]
January 11, 2017- The Cooley’s Anemia Foundation is pleased to announce that Janelle Trieu has been named recipient of the 2016 CAF-ApoPharma Distinguished Scholar Award. The Award is presented to U.S. individuals with a clinically significant form of thalassemia who have chosen to pursue postgraduate doctoral level studies in medicine or science. Janelle is currently […]
July 10, 2016 – The Cooley’s Anemia Foundation is accepting applications from individuals with thalassemia for the 2016 CAF ApoPharma Distinguished Scholar Award. The CAF-ApoPharma Distinguished Scholar Award, which was established in 2014, is made possible through a grant from pharmaceutical manufacturer ApoPharma. CAF will award up to two scholarships to a U.S. citizen(s) with […]
January 5, 2016- The Cooley’s Anemia Foundation is pleased to announce that Aaron Cheng has been named recipient of the 2015 CAF-ApoPharma Distinguished Scholar Award. The Award is presented to U.S. individuals with a clinically significant form of thalassemia who have chosen to pursue postgraduate doctoral level studies in medicine or science. Aaron is currently […]
June 22, 2015 – The Cooley’s Anemia Foundation is accepting applications from individuals with thalassemia for the 2015 CAF ApoPharma Distinguished Scholar Award. The CAF-ApoPharma Distinguished Scholar Award, which was established last year, is made possible through a grant from pharmaceutical manufacturer ApoPharma. CAF will award up to two scholarships to a U.S. citizen(s) with a clinically significant […]
April 12, 2013 – The Cooley’s Anemia Foundation is pleased to announce the receipt of an unrestricted educational grant in the amount of $100,000 from ApoPharma. This money will be used to support a range of CAF programs and services, including major sponsorship of the upcoming CAF 2013 Patient~Family Conference in Philadelphia on June 28-30. […]
January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]
March 15, 2012 – Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and […]
December 5, 2011 – The oral chelator Ferriprox, recently approved by the U.S. Food and Drug Administration, is available to U.S. patients as of today (December 5, 2011). The drug’s manufacturer, ApoPharma, has set up a system whereby all U.S. patients who have been receiving Ferriprox under a Treatment IND program (also called “compassionate use”) […]
September 20, 2011 – FerroKin BioSciences announced on September 19 that the first dose has been administered in an international Phase 2 study of FBS0701, a novel once-daily oral iron chelator in development for the treatment of transfusional iron overload. This is an Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, […]
